A Phase 3 interventional study of Semaglutide and Insuline glargine U100 (reduced) in Diabetes Mellitus, Type 2 and Obesity, sponsored by Novo Nordisk A/S. Completed at 239 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-11.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 163 studies testing semaglutide in Diabetes Mellitus, Type 2 — 35 open to participants now, 45 under way, 9 of them phase 3. Semaglutide · Diabetes Mellitus, Type 2.
Among the 163 studies testing semaglutide in Diabetes Mellitus, Type 2, this one is the 32nd largest by enrollment, is one of 18 that started in 2022, is one of 57 in phase 3, and was the 105th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →35 of the 163 studies testing semaglutide in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:
Mapi Pharma Ltd. · Sites in Israel
Ages 18–64
Emory University · Sites in United States
Ages 65+ · Women only
Daewoong Pharmaceutical Co. LTD. · Sites in Korea, Republic of
Ages 19–64 · Healthy volunteers
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18–70
Ottawa Heart Institute Research Corporation · Sites in Canada
Ages 18+
By country, each count listing its studies:
Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, semaglutide is the treatment under test here. Read study by study →
163 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 44 · Phase 2 14 · Phase 3 58 · Phase 4 40
First in 2007; this study’s year is marked. 18 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 573 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 104 across the 163 interventional studies. Of the 109 that completed or were terminated, 54 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
100 of 163 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S: 25 open now, 29 under way, 11 of them phase 3. Of 603 finished, 174 (29%) have results posted.
Among the 643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S, this one is the 81st largest by enrollment of the 428 interventional ones that give a count, is one of 24 that started in 2022, is one of 187 in phase 3, and was the 570th registered.
Novo Nordisk A/S’s Diabetes Mellitus, Type 2 studies by the year they started, since 1997.
14 of the studies testing semaglutide in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07059377Phase 3Ottawa Heart Institute Research CorporationSemaglutide for Smoking Cessation in Patients With Diabetes | 2026-12 |
| NCT03811561Phase 3Novo Nordisk A/SA Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes | 2027-11-07 |
| NCT05067621Yale UniversitySemaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease | 2026-12 |
| NCT06715514Lia BallyMenopausal Hormone Therapy, GLP-1 Agonists, and Glucose and Energy Homeostasis in Postmenopausal Women With Overweight/Obesity and Impaired Glucose Homeostasis | 2026-12-17 |
| NCT06461377The First Affiliated Hospital with Nanjing Medical UniversityThe Ameliorative Effects of GLP-1RA on Diabetic Cardiac Autonomatic Neuropathy | 2026-12-31 |
Add all 14 to your calendar (.ics) → With an account.
Among the 163 studies testing semaglutide in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novo Nordisk A/S’s 643 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
This study compares semaglutide, together with a lower dose of insulin glargine, to a higher dose of insulin glargine in participants with type 2 diabetes. The study looks at how well the study medicines control blood glucose levels. Participants will either get semaglutide together with a lower dose of insulin glargine or a higher dose of insulin glargine. The study will last for about 47 weeks (approximately 11 months). Participants will have 9 clinic visits, 15 phone/video calls and 1 home visit. Participants will be asked to wear a sensor that measures their blood sugar all the time in 2 periods of 10 days during the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The treatment can be with or without sodium glucose cotransporter 2 (SGLT-2) inhibitors.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will initially receive 0.25 milligrams (mg) once-weekly semaglutide subcutaneously (s.c.) and the dose will be gradually escalated to 2 mg as an add-on to dose-reduced insulin glargine s.c. given once-daily. Insulin glargine U100 will be reduced by 10 U at the initiation of semaglutide and then again at each semaglutide dose escalation. Insulin glargine dose will be adjusted based on the mean of three pre-breakfast self-measured plasma glucose (SMPG) values (target SMPG: 4.4-7.2 millimoles per litre (mmol/L)).
Drug: Semaglutide · Drug: Insuline glargine U100 (reduced)
Participants will receive titrated insuline glargine U100 s.c. once-daily. Insulin glargine U100 dose will be adjusted based on the mean of three pre-breakfast SMPG values (target SMPG: 4.4-7.2 mmol/L).
Drug: Insuline glargine U100 (titrated)
Participants will receive once-weekly semaglutide s.c. for 40 weeks. Semaglutide 0.25 mg will be given at week 0 and then the dose will be escalated at weeks 4, 8 and 12 to 0.5 mg, 1 mg, 2 mg respectively.
Participants will receive insulin glargine U100 s.c. once-daily. Insulin glargine dose will be reduced by 10 U at initiation of semaglutide and then again at each semaglutide dose escalation up to 40 weeks. The dose will be adjusted based on the mean of three pre-breakfast SMPG values (target SMPG: 4.4-7.2 mmol/L).
Participants will receive titrated insulin glargine U100 s.c. once-daily up to 40 weeks. The dose will be adjusted based on the mean of three pre-breakfast SMPG values (target SMPG: 4.4-7.2 mmol/L).
Change in Glycated Haemoglobin (HbA1c) [Noninferiority]
Change in HbA1c (Noninferiority) from baseline (Week 0) to end of treatment (Week 40) were reported. Here noninferiority was assessed based on the clinically acceptable margin of 0.3%-point for the mean treatment difference in HbA1c.
Time frame: From baseline (week 0) to end of treatment (week 40)
Change in Body Weight
Change in body weight from baseline (Week 0) to end of treatment (Week 40) were reported. Body weight was measured in unit 'Kilogram (kg)'.
Time frame: From baseline (week 0) to end of treatment (week 40)
Percentage Change in Daily Insulin Dose
Percentage change in daily insulin dose from baseline (Week 0) to end of treatment (Week 40) were reported. Percentage change from baseline to week 40 in insulin dose (%) was calculated as: (\[insulin dose at week 40\] - \[insulin dose at baseline\]) / \[insulin dose at baseline\] × 100.
Time frame: From baseline (week 0) to end of treatment (week 40)
Change in Glycated Haemoglobin (HbA1c ) [Superiority]
Change in HbA1c (Superiority) from baseline (Week 0) to end of treatment (Week 40) were reported.
Time frame: From baseline (week 0) to end of treatment (week 40)
Score of Diabetes Treatment Satisfaction Questionnaire - Change Version (DTSQc)
Score of Diabetes Treatment Satisfaction Questionnaire - change version (DTSQc) at end of treatment (week 40) were reported. The DTSQc provided a measure of how satisfied participants were with their current diabetes treatment compared with previous treatment. It consisted of 8 questions, which were to be answered on a Likert scale from -3 to +3 (-3 = much less satisfied now to +3 = much more satisfied now), with 0 (midpoint) representing no change. Out of 8 questions, 6 questions related to treatment satisfaction were summed to produce a total score. The DTSQc total treatment satisfaction score ranged from -18 to +18, with higher scores associated with greater treatment satisfaction.
Time frame: At end of treatment (week 40)
Number of Participants Achieving Insulin Dose = 0 Units/mL (U)
Number of participants achieving Insulin dose = 0 U at the end of treatment (Week 40) were reported.
Time frame: At end of treatment (week 40)
Number of Participants Achieving Insulin Dose Reduced From Baseline by at Least 50%
Number of participants achieving Insulin dose reduced from baseline by at least 50% by end pf treatment (Week 40) were reported.
Time frame: At end of treatment (week 40)
Number of Participants Achieving HbA1c Less Than (<) 7%
Number of participants achieving HbA1c \< 7% at the end of treatment (Week 40) were reported.
Time frame: At end of treatment (week 40)
Number of Severe Hypoglycaemic Episodes (Level 3)
Number of severe hypoglycaemic episodes (level 3) from baseline (week 0) to end of treatment (week 40) were reported. Severe hypoglycaemia (level 3) was defined as hypoglycaemia with severe cognitive impairment requiring external assistance for recovery.
Time frame: From baseline (week 0) to end of treatment (week 40)
Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (<3.0 mmol/L (54 mg/dL), Confirmed by Blood Glucose (BG) Meter)
Number of clinically significant hypoglycaemic episodes (level 2) (\<3.0 mmol/L (54 mg/dL), confirmed by BG meter) from baseline (week 0) to end of treatment (week 40) were reported. Clinically significant hypoglycaemia (level 2) was defined as plasma glucose value of less than (\<) 3.0 mmol/L (54 mg/dL) confirmed by BG meter.
Time frame: From baseline (week 0) to end of treatment (week 40)
Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (<3.0 mmol/L (54 mg/dL), Confirmed by BG Meter) or Severe Hypoglycaemic Episodes (Level 3)
Number of clinically significant hypoglycaemic episodes (level 2) (\<3.0 mmol/L (54 mg/dL), confirmed by BG meter) or severe hypoglycaemic episodes (level 3) from baseline (week 0) to end of treatment (week 40) were reported. Clinically significant hypoglycaemia (level 2) was defined as plasma glucose value of less than (\<) 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3) was defined as hypoglycaemia with severe cognitive impairment requiring external assistance for recovery.
Time frame: From baseline (week 0) to end of treatment (week 40)
Number of Participants Achieving HbA1c Reduced From Baseline by at Least 0.3%-Points and Insulin Dose Reduced From Baseline, No Hypoglycaemic Episodes (< 3.9 mmol/L (70 mg/dL) Confirmed by BG Meter) and No Weight Gain
Number of Participants achieving HbA1c reduced from baseline by at least 0.3%-points and Insulin dose reduced from baseline, No hypoglycaemic episodes (\< 3.9 mmol/L (70 mg/dL) confirmed by BG meter) and No weight gain at the end of treatment (Week 40) were reported.
Time frame: At end of treatment (week 40)
Change in Score of Diabetes Treatment Satisfaction Questionnaire - Status Version (DTSQs)
Score of Diabetes Treatment Satisfaction Questionnaire - status version (DTSQs) at end of treatment (week 40) were reported. The status version measures a patient's current satisfaction with treatment using a 0-6 scale for each item; higher scores indicate greater satisfaction with the present treatment (absolute/status level). The DTSQs total treatment satisfaction score ranged from 0 to 36, with higher scores associated with greater treatment satisfaction.
Time frame: From baseline (week 0) to end of treatment (week 40)
Change in Score of Short Form 36 Version 2 (SF-36 v2)
Change in SF-36 physical and mental component from baseline (week 0) to end of treatment (Week 40) were presented. SF-36 is self-administered questionnaire that measures each of following 8 health domains: physical functioning, role limitations due to physical problems (role-physical), social functioning, bodily pain, mental health, role limitations due to emotional problems (role-emotional), vitality, and general health perception. There are also 2 component scores derived from the 8 subscale scores: mental component summary and physical component summary. Physical component summary contains physical functioning, role-physical, bodily pain and general health and mental component summary contain vitality, social functioning, role-emotional and mental health. Each SF-36 domain and component summary score ranges from 0 to 100, higher scores reflect better participant health status. A positive change score indicates an improvement since baseline.
Time frame: From baseline (week 0) to end of treatment (week 40)
The study was conducted at 140 sites that recruited participants in 9 countries.
| Milestone | Insuline Glargine U100 (Reduced) + Semaglutide | Insuline Glargine U100 (Titrated) |
|---|---|---|
| Started | 288 | 285 |
| Safety analysis set (sas) | 288 | 284 |
| Full analysis set (fas) | 288 | 285 |
| Completed | 283 | 275 |
| Not completed | 5 | 10 |
| Withdrew: Death | 1 | 1 |
| Withdrew: Physician decision | 1 | 2 |
| Withdrew: Lost to follow-up | 2 | 2 |
| Withdrew: Withdrawal by subject | 1 | 5 |
Change in HbA1c (Noninferiority) from baseline (Week 0) to end of treatment (Week 40) were reported. Here noninferiority was assessed based on the clinically acceptable margin of 0.3%-point for the mean treatment difference in HbA1c.
| Percentage point of HbA1c | Insuline Glargine U100 (Reduced) + Semaglutide | Insuline Glargine U100 (Titrated) |
|---|---|---|
| Change in Glycated Haemoglobin (HbA1c) [Noninferiority] | -1.37 ± 0.84 | -0.65 ± 0.92 |
Change in body weight from baseline (Week 0) to end of treatment (Week 40) were reported. Body weight was measured in unit 'Kilogram (kg)'.
| Kilograms | Insuline Glargine U100 (Reduced) + Semaglutide | Insuline Glargine U100 (Titrated) |
|---|---|---|
| Change in Body Weight | -7.97 ± 5.62 | 0.39 ± 4.08 |
Percentage change in daily insulin dose from baseline (Week 0) to end of treatment (Week 40) were reported. Percentage change from baseline to week 40 in insulin dose (%) was calculated as: (\[insulin dose at week 40\] - \[insulin dose at baseline\]) / \[insulin dose at baseline\] × 100.
| Percentage change of daily insulin dose | Insuline Glargine U100 (Reduced) + Semaglutide | Insuline Glargine U100 (Titrated) |
|---|---|---|
| Percentage Change in Daily Insulin Dose | -15.11 ± 87.25 | 103.42 ± 142.38 |
Change in HbA1c (Superiority) from baseline (Week 0) to end of treatment (Week 40) were reported.
| Percentage-point of HbA1c | Insuline Glargine U100 (Reduced) + Semaglutide | Insuline Glargine U100 (Titrated) |
|---|---|---|
| Change in Glycated Haemoglobin (HbA1c ) [Superiority] | -1.37 ± 0.84 | -0.65 ± 0.92 |
Score of Diabetes Treatment Satisfaction Questionnaire - change version (DTSQc) at end of treatment (week 40) were reported. The DTSQc provided a measure of how satisfied participants were with their current diabetes treatment compared with previous treatment. It consisted of 8 questions, which were to be answered on a Likert scale from -3 to +3 (-3 = much less satisfied now to +3 = much more satisfied now), with 0 (midpoint) representing no change. Out of 8 questions, 6 questions related to treatment satisfaction were summed to produce a total score. The DTSQc total treatment satisfaction score ranged from -18 to +18, with higher scores associated with greater treatment satisfaction.
| Score on a scale | Insuline Glargine U100 (Reduced) + Semaglutide | Insuline Glargine U100 (Titrated) |
|---|---|---|
| Score of Diabetes Treatment Satisfaction Questionnaire - Change Version (DTSQc) | 14.69 ± 4.65 | 12.11 ± 6.84 |
Number of participants achieving Insulin dose = 0 U at the end of treatment (Week 40) were reported.
| Participants | Insuline Glargine U100 (Reduced) + Semaglutide | Insuline Glargine U100 (Titrated) |
|---|---|---|
| Number of Participants Achieving Insulin Dose = 0 Units/mL (U) | 37 | 0 |
Number of participants achieving Insulin dose reduced from baseline by at least 50% by end pf treatment (Week 40) were reported.
| Participants | Insuline Glargine U100 (Reduced) + Semaglutide | Insuline Glargine U100 (Titrated) |
|---|---|---|
| Number of Participants Achieving Insulin Dose Reduced From Baseline by at Least 50% | 103 | 2 |
Number of participants achieving HbA1c \< 7% at the end of treatment (Week 40) were reported.
| Participants | Insuline Glargine U100 (Reduced) + Semaglutide | Insuline Glargine U100 (Titrated) |
|---|---|---|
| Number of Participants Achieving HbA1c Less Than (<) 7% | 224 | 111 |
Number of severe hypoglycaemic episodes (level 3) from baseline (week 0) to end of treatment (week 40) were reported. Severe hypoglycaemia (level 3) was defined as hypoglycaemia with severe cognitive impairment requiring external assistance for recovery.
| Episodes | Insuline Glargine U100 (Reduced) + Semaglutide | Insuline Glargine U100 (Titrated) |
|---|---|---|
| Number of Severe Hypoglycaemic Episodes (Level 3) | 6 | 14 |
Number of clinically significant hypoglycaemic episodes (level 2) (\<3.0 mmol/L (54 mg/dL), confirmed by BG meter) from baseline (week 0) to end of treatment (week 40) were reported. Clinically significant hypoglycaemia (level 2) was defined as plasma glucose value of less than (\<) 3.0 mmol/L (54 mg/dL) confirmed by BG meter.
| Episodes | Insuline Glargine U100 (Reduced) + Semaglutide | Insuline Glargine U100 (Titrated) |
|---|---|---|
| Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (<3.0 mmol/L (54 mg/dL), Confirmed by Blood Glucose (BG) Meter) | 16 | 32 |
Number of clinically significant hypoglycaemic episodes (level 2) (\<3.0 mmol/L (54 mg/dL), confirmed by BG meter) or severe hypoglycaemic episodes (level 3) from baseline (week 0) to end of treatment (week 40) were reported. Clinically significant hypoglycaemia (level 2) was defined as plasma glucose value of less than (\<) 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3) was defined as hypoglycaemia with severe cognitive impairment requiring external assistance for recovery.
| Episodes | Insuline Glargine U100 (Reduced) + Semaglutide | Insuline Glargine U100 (Titrated) |
|---|---|---|
| Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (<3.0 mmol/L (54 mg/dL), Confirmed by BG Meter) or Severe Hypoglycaemic Episodes (Level 3) | 22 | 46 |
Number of Participants achieving HbA1c reduced from baseline by at least 0.3%-points and Insulin dose reduced from baseline, No hypoglycaemic episodes (\< 3.9 mmol/L (70 mg/dL) confirmed by BG meter) and No weight gain at the end of treatment (Week 40) were reported.
| Participants | Insuline Glargine U100 (Reduced) + Semaglutide | Insuline Glargine U100 (Titrated) |
|---|---|---|
| Number of Participants Achieving HbA1c Reduced From Baseline by at Least 0.3%-Points and Insulin Dose Reduced From Baseline, No Hypoglycaemic Episodes (< 3.9 mmol/L (70 mg/dL) Confirmed by BG Meter) and No Weight Gain | 138 | 6 |
Score of Diabetes Treatment Satisfaction Questionnaire - status version (DTSQs) at end of treatment (week 40) were reported. The status version measures a patient's current satisfaction with treatment using a 0-6 scale for each item; higher scores indicate greater satisfaction with the present treatment (absolute/status level). The DTSQs total treatment satisfaction score ranged from 0 to 36, with higher scores associated with greater treatment satisfaction.
| Score on scale | Insuline Glargine U100 (Reduced) + Semaglutide | Insuline Glargine U100 (Titrated) |
|---|---|---|
| Change in Score of Diabetes Treatment Satisfaction Questionnaire - Status Version (DTSQs) | 4.56 ± 7.04 | 2.17 ± 7.04 |
Change in SF-36 physical and mental component from baseline (week 0) to end of treatment (Week 40) were presented. SF-36 is self-administered questionnaire that measures each of following 8 health domains: physical functioning, role limitations due to physical problems (role-physical), social functioning, bodily pain, mental health, role limitations due to emotional problems (role-emotional), vitality, and general health perception. There are also 2 component scores derived from the 8 subscale scores: mental component summary and physical component summary. Physical component summary contains physical functioning, role-physical, bodily pain and general health and mental component summary contain vitality, social functioning, role-emotional and mental health. Each SF-36 domain and component summary score ranges from 0 to 100, higher scores reflect better participant health status. A positive change score indicates an improvement since baseline.
| Score on a scale | Insuline Glargine U100 (Reduced) + Semaglutide | Insuline Glargine U100 (Titrated) |
|---|---|---|
| Physical Component Score | 3.18 ± 7.47 | 0.12 ± 6.67 |
| Mental Component Score | 1.63 ± 9.02 | 0.93 ± 7.39 |
Collected over From baseline (week 0) to the end of study (week 45). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| INSULIN GLARGINE (REDUCED) + SEMAGLUTIDE | 1/288 (0.3%) | 17/288 (5.9%) | 92/288 (31.9%) |
| INSULIN GLARGINE (TITRATED) | 1/284 (0.4%) | 15/284 (5.3%) | 13/284 (4.6%) |
| Event | INSULIN GLARGINE (REDUCED) + SEMAGLUTIDE | INSULIN GLARGINE (TITRATED) |
|---|---|---|
| Atrial fibrillationCardiac disorders | 0/288 | 2/284 |
| Chest painGeneral disorders | 2/288 | 0/284 |
| Acute myocardial infarctionCardiac disorders | 1/288 | 1/284 |
| AnaemiaBlood and lymphatic system disorders | 0/288 | 1/284 |
| Aortic dissectionVascular disorders | 0/288 | 1/284 |
| Cardiac failureCardiac disorders | 0/288 | 1/284 |
| Confusional statePsychiatric disorders | 0/288 | 1/284 |
| Gallbladder disorderHepatobiliary disorders | 0/288 | 1/284 |
| Humerus fractureInjury, poisoning and procedural complications | 0/288 | 1/284 |
| HyperglycaemiaMetabolism and nutrition disorders | 0/288 | 1/284 |
| Event | INSULIN GLARGINE (REDUCED) + SEMAGLUTIDE | INSULIN GLARGINE (TITRATED) |
|---|---|---|
| NauseaGastrointestinal disorders | 53/288 | 2/284 |
| DiarrhoeaGastrointestinal disorders | 39/288 | 12/284 |
| VomitingGastrointestinal disorders | 28/288 | 1/284 |
| ConstipationGastrointestinal disorders | 23/288 | 0/284 |
| Decreased appetiteMetabolism and nutrition disorders | 21/288 | 2/284 |
FAS included all randomized participants and were analysed according to the planned intervention.
| Age, Continuous(Years) | Insuline Glargine U100 (Reduced) + Semaglutide | Insuline Glargine U100 (Titrated) | Total |
|---|---|---|---|
| Mean | 61.7 ± 9.7 | 60.5 ± 10.3 | 61.1 ± 10.0 |
| Sex: Female, Male(Participants) | Insuline Glargine U100 (Reduced) + Semaglutide | Insuline Glargine U100 (Titrated) | Total |
|---|---|---|---|
| Female | 124 | 129 | 253 |
| Male | 164 | 156 | 320 |
| Ethnicity (NIH/OMB)(Participants) | Insuline Glargine U100 (Reduced) + Semaglutide | Insuline Glargine U100 (Titrated) | Total |
|---|---|---|---|
| Hispanic or Latino | 27 | 31 | 58 |
| Not Hispanic or Latino | 261 | 254 | 515 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Insuline Glargine U100 (Reduced) + Semaglutide | Insuline Glargine U100 (Titrated) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 33 | 22 | 55 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Black or African American | 10 | 9 | 19 |
| White | 243 | 253 | 496 |
| More than one race | 1 | 0 | 1 |
| Unknown or Not Reported | 0 | 1 | 1 |
Showing the first 100 of 239 sites across 12 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Data sharing details ↗ · novonordisk-trials.com
Ran from Aug 2022 to primary completion in Mar 2025, 30 months.
Results were first posted in May 2026, 1 year 2 months after primary completion.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 30 months is above that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Semaglutide